DDrare: Database of Drug Development for Rare Diseases

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 100 mg AP1189; ABATACEPT; ACH-0144471; ACTH; ACTHar; ALXN2040 (ACH-0144471); AP1189; APL-2; AVACOPAN; Abatacept; Acetaminophen; Acetate; Acid mycophenolic (Myfortic); Acthar; Acthar Gel; Adalimumab; Adalimumab (Humira); Adrenocorticotrophic hormone ACTH; Advagraf 0,5mg; Advagraf 1mg; Advagraf 5mg; Aldosterone; Aliskiren; Amoxicillin; Angiotensin; Angiotensin II; Apixaban; Apixaban 5 MG; Aprovel (150 mg); Aprovel 150 mg Tablets; Atorvastatin; Atrasentan; Avacopan; BELIMUMAB; BENLYSTA; BENLYSTA®; BENLYSTA® (belimumab); BMS-188667; Bardoxolone; Bardoxolone methyl; Bardoxolone methyl capsules; Basiliximab; Belimumab; Belimumab 10 mg; Benlysta; Benlysta (belimumab); Bleselumab; CCX140; CCX140-B; CCX168; CDX; CDX-1135; CXA-10; CYCLOPHOSPHAMIDE; Calcium; Chlorambucil; Ciclofosfamida; Ciclosporin; Clarithromycin; Conventional therapy; Corticosteroid; Corticotropin; CsA; CyA; Cyclophosphamide; Cyclophosphamide and steroids; Cyclosporin; Cyclosporin, low dose steroid; Cyclosporine; Cyclosporins; D-Galactose; Dacortín 2,5mg; Dacortín 30mg; Dacortín 5mg; Dalteparin; Danicopan; Danzhu Fuyuan Granule; Dapagliflozin; Daratumumab; Device: LIPOSORBER® LA-15; Device: LIPOSORBER® LA-15 System; Dexamethasone; Diphenhydramine; ECULIZUMAB; ENDOXAN BAXTER*50CPR RIV 50MG; Eculizumab; Eliquis; Enalapril; Endoxan; Evolocumab; Experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab); FCM; FG-3019; FK506; Filgotinib; Fluvastatin; Fragmin; Fresolimumab; GC1008; GFB-887; GSK1550188; GSK1550188 (Belimumab); GZ402669; Galactose; Genoxal; Gold; H.P. Acthar Gel; Hydroxychloroquine; INN not available yet; IRBESARTAN; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Intravenous injection; Irbesartan; Irbesartan tablets; Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03; Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved in the USA) Generic tablets distributed by Solco Healthcare US, LLC; Jianpixiaozhong particles and Wuse Dietotherapy; LA; LNP023; LT4; Lanraplenib; Lansoprazole; Lansoprazole, amoxicillin, clarithromycin; Lisinopril; Lisinopril, losartan, and atorvastatin; Losartan; Losartan Tablets & QingReMoShen Granule; Losmapimod; MABTHERA; MABTHERA*EV 1FL 50ML 500MG; MEDROL*10CPR DIV 4MG; METHYLPREDNISOLONE; MMF; MMF and Dexamethasone; MOR03087; MOR202; MP and CTX; MabThera; MabThera 100 mg concentrate for solution for infusion; MabThera 500 mg concentrate for solution for infusion; Medrol; Mesenchymal stem cells; Methylprednisolone; Methylprednisone; Mizoribine; Mycophenolate; Mycophenolate Mofetil; Mycophenolate Mofetil (MMF); Mycophenolate mofetil; Mycophenolate mofetil orally 1000 mg twice a day (BID); Mycophenolate mofetil, low dose steroid; Mycophenolate sodium; Mycophenolic acid; Mycophenolic sodium; Myfortic; Myfortic 180mg Tablets; Myfortic 360mg Tablets; Myfortic plus low-dose steroid; Narsoplimab; Neoral; OMS721 (narsoplimab); Obinutuzumab; Oral Cyclosporine; Orencia; Other: D5W; Other: Normal Saline; Over-encapsulated 75 mg Irbesartan Tablets; Over-encapsulated Irbesartan Tablets; PF-06730512; PREDNISOLONE; PREDNISOLONE ACETATE; PREDNISONE; Pegcetacoplan; Pentoxifylline; Perindopril; Pirfenidone; Ponticelli Regimen; Prednisolone; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil; Prednisona; Prednisone; Prednisone 0,5 mg/kg orally on alternate days; Prednisone, FK506, MMF; Prednisone, ciclosporin and mycophenolate mofetil; Procedure: Plasma exchange; Procedure: Plasmapheresis; Prograf; Propagermanium; RE-021; RE-021 (Sparsentan); RITUXIMAB; RTX; Repository Corticotropin Injection; Rituximab; Rituximab Infusion; Rosiglitazone; Rosiglitazone (Avandia); SPARSENTAN; Sirolimus; Soliris; Solondo; Sparsentan; Sparsentan/Over-encapsulated Sparsentan tablet; Sparsentan/Over-encapsulated Sparsentan tablets; Steroid & Cyclosporin; Sulfate; Symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin); Synacthen Depot; Synacthen Depot 1mg; TACROLIMUS; TRU-015; TRUXIMA; TRUXIMAB; TW; Tacrolimus; Tacrolimus Capsules; Tacrolimus combined with prednisone; Tetracosactide; Tetracosactide hexacetaat; The Comprehensive Treatment Regimen of Traditional Chinese Medicine; The immunosuppressive agents; Tripterygium; Tripterygium Wilfordii; Tripterygium wilfordii; Tripterygium wilfordii (TW); Truxima; URBASON*IM EV 1F 250MG+1F 5ML; Urbason; VB119; VX-147; VX147; Valproic Acid; Valproic acid; Valsartan; Vitamin D; Voclosporin; Zestril; [CCX140-B];  LNP023 HYDROCHLORIDE SALT

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-TRC-14005064	2014-09-01	2014-08-06	A prospective study on the safety and efficacy of treatment with Qiluxiaobai formula for CKD 2-3 stage	Investigation on the Mechanisms Of Invigorating Spleen Dissipating Dampness Principle On The Treatment Of Podocyte Injury In Focal Segmental Glomerulosclerosis	chronic kidney disease	1:basic treatment and losartan K 50mg qd;2:basic treatment and QLXB formula 200ml qd ;	Shanghai University of T.C.M	NULL	Recruiting	18	60	Both	1:50;2:50;		China
2	NCT01845688 (ClinicalTrials.gov)	November 2011	29/4/2013	Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy	Efficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical Study	Idiopathic Membranous Nephropathy	Drug: Losartan Tablets & QingReMoShen Granule;Drug: Losartan Tablets & Placebo Granule	wanglin	NULL	Active, not recruiting	18 Years	70 Years	Both	72	N/A	China
3	NCT00814255 (ClinicalTrials.gov)	December 2008	22/12/2008	Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial	Novel Therapies for Resistant Focal Segmental Glomerulosclerosis	Focal Segmental Glomerulosclerosis	Drug: Adalimumab;Drug: Lisinopril , losartan, and atorvastatin;Drug: galactose	New York University School of Medicine	University of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	1 Year	65 Years	All	32	Phase 2	United States;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

ChiCTR-TRC-14005064

2014-09-01

2014-08-06

A prospective study on the safety and efficacy of treatment with Qiluxiaobai formula for CKD 2-3 stage

Investigation on the Mechanisms Of Invigorating Spleen Dissipating Dampness Principle On The Treatment Of Podocyte Injury In Focal Segmental Glomerulosclerosis

chronic kidney disease

1:basic treatment and losartan K 50mg qd;2:basic treatment and QLXB formula 200ml qd ;

Shanghai University of T.C.M

NULL

Recruiting

Both

1:50;2:50;

China

NCT01845688
(ClinicalTrials.gov)

November 2011

29/4/2013

Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy

Efficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical Study

Idiopathic Membranous Nephropathy

Drug: Losartan Tablets & QingReMoShen Granule;Drug: Losartan Tablets & Placebo Granule

wanglin

NULL

Active, not recruiting

18 Years

70 Years

Both

N/A

China

NCT00814255
(ClinicalTrials.gov)

December 2008

22/12/2008

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

Novel Therapies for Resistant Focal Segmental Glomerulosclerosis

Focal Segmental Glomerulosclerosis

Drug: Adalimumab;Drug: Lisinopril , losartan, and atorvastatin;Drug: galactose

New York University School of Medicine

University of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

1 Year

65 Years

All

Phase 2

United States;Canada